HIV Drugs Market Outlook 2025–2029: Emerging Opportunities and Key Drivers

Uncover key drivers, emerging technologies, and competitive movements shaping the hiv drugs market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The HIV Drugs Market And What Value Is Projected For 2029?

The HIV drugs market has demonstrated consistent expansion in its size over recent years. It is anticipated to grow from $35.33 billion in 2024 to $36.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.5%. This historical growth can be primarily linked to factors such as increased government support and initiatives, a rise in healthcare expenditure, greater spending on HIV research and development, a higher incidence of HIV infection, heightened awareness, and economic growth within emerging markets.

The HIV drugs market size is projected to experience consistent expansion over the next few years. It is expected to reach “$41.55 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 3.3%. This anticipated growth can be attributed to several factors such as increased government support and initiatives, a rise in healthcare expenditure, greater spending on HIV research and development, an elevated incidence of HIV infection, heightened awareness, and economic prosperity in emerging markets. Significant trends during the forecast period involve investments in 3D bioprinting technology, the introduction of new product innovations, the development of multi-class combination products for HIV treatment, and participation in strategic collaborations and agreements.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

What Factors Are Boosting The HIV Drugs Market?

Heightened public understanding of HIV diagnosis and its treatment options serves as a key impetus for the expansion of the HIV drug market. HIV/AIDS is recognized as one of the most chronic diseases, and its widespread prevalence across nearly all regions of the world has generated an unprecedented level of awareness about the condition. For instance, in July 2024, the United Nations International Children’s Emergency Fund (UNICEF), a US-based humanitarian aid organization, reported that in 2023, an estimated 40.0 million people were living with HIV worldwide. Among these individuals, 2.38 million were children aged 0-19. Each day in 2023, approximately 685 children became infected with HIV, and about 250 children died from AIDS. Therefore, increasing awareness among people regarding the diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug market.

What Are The Core Segmentation Criteria In The HIV Drugs Market?

The hiv drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types

2) By Administration: Oral, Parenteral

3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:

1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs

2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs

3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs

4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs

5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

Which Emerging Trends Are Reshaping The HIV Drugs Market Landscape?

Major companies in the HIV drugs market are forming strategic partnerships to manufacture Lenacapavir. These collaborations aim to accelerate drug development, expand access to treatments, and enhance their global market presence. Lenacapavir is a first-in-class HIV-1 capsid inhibitor that works effectively in combination with other antiretrovirals and targets multiple stages of the HIV lifecycle, making it a promising option for patients with limited treatment alternatives. For instance, in August 2023, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, and Hetero, an India-based pharmaceutical company partnered with Gilead Sciences Inc. With this partnership, Dr. Reddy’s Laboratories and Hetero aims to manufacture and distribute the HIV drug lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This initiative seeks to broaden access to this innovative treatment, which is particularly beneficial for heavily treatment-experienced patients with multi-drug-resistant HIV. Gilead Sciences Inc. is a US-based biopharmaceutical company.

Which Players Are Shaping The Competitive Landscape Of The HIV DrugsXX Market?

Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China’s National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

What Regional Trends Are Shaping Growth In The HIV Drugs Market?

North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2834&type=smp

Browse Through More Reports Similar to the Global HIV Drugs Market 2025, By The Business Research Company

Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Hormonal Contraceptives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795